Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

PHASE4CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions
TumorsHyperuricemiaTumor Lysis Syndrome
Interventions
DRUG

Rasburicase (SR29142)

Trial Locations (7)

10595

New York Medical College, Valhalla

19104

University of Pennsylvania Health Systems, Philadelphia

32209

University of Florida Health Science Center at Jacksonville, Jacksonville

73104

University of Oklahoma HSC, Oklahoma City

80218

Rocky Mountain Cancer Center, Denver

94704

Alta Bates Comprehensive Cancer Center, Berkley

26506-9162

Mary Babb Randolph Cancer Center, Morgantown

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY